Company profile
Evommune, Inc.
NYSE: EVMN · Healthcare · Biotechnology
#678 of 1,418 Healthcare companies by revenue43rd-percentile growth
EA Score
45DFH 72DQ 5GM —SS 43
v0.1 · 55/100 weight · provisional
↑ return on equity, return on assets · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$10.0M
Rev growth YoY (TTM)
+233.3%
Net income (FY)
$758.5k
Employees
48
as of 2026-08-14
Market cap
$510.6M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$6.6M$6.6M2025
Net income$758.5k$758.5k2025
Operating income-$1.4M-$1.4M2025
Total assets$9.1M$9.1M2025
Liabilities$7.6M$7.6M2025
Equity$1.5M$1.5M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Evommune, Inc.’s revenue?
Evommune, Inc. booked $6.6M in FY2025 revenue, growing 0.7% year over year — about the middle of the pack among Healthcare companies we track, at a 11.5% net margin.
Peers · Healthcare
Reliq Health Technologies Inc.——Pacific Health Care Organization, Inc.74BFate Therapeutics, Inc.43DEncision Inc.——GlobeImmune, Inc.——Kyntra Bio, Inc.60CNeighbors
Santa Clara →Key facts
CEOLuis C. Pena
SectorHealthcare
IndustryBiotechnology
HeadquartersPalo Alto, CA
ExchangeNYSE: EVMN
Employees48
IPO date2025-11-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.